ADDvise receives order worth USD 1.4 million

21-05-2024   Regulatory press release

Axelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and rental of medical and laboratory equipment. The order value amounts to USD 1.4 million. Delivery will take place over a four-year period starting in Q3 2024.


For further information, please contact:

Rikard Akhtarzand, CEO

+46 (0) 76-525 90 71


Important information

This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on May 21, 2024, at 12:30 CEST.


About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at